In late March 2013, Crossdock Development was approached by Catamaran Corporation and Jones Lang Lasalle to construct a new 107,500 s.f. prototype building for BriovaRx, Catamaran’s new subsidiary providing specialty pharmaceutical care to patients with complex and chronic conditions.

To capitalize on current market trends and conditions the BriovaRx facility was required to be able to obtain a pharmacy license by the end of October 2013 and become fully operational by January 2014.

Crossdock Development designed and constructed the BriovaRx facility in an unprecedented six-month time period that met or exceeded Catamaran’s milestones and expectations.


Stay Connected

"*" indicates required fields

This field is for validation purposes and should be left unchanged.